Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research

Prostate

Volumn 31, Issue 3, 1997, Pages 198-203

  Pousette, Åke ^a   Carlström, Kjell ^a   Henriksson, Peter ^a   Grande, Mirtha ^a   Stege, Reinhard ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

biopsy; ploidies; prostatic neoplasm; PSA

Indexed keywords

ESTRAMUSTINE; ESTROGEN;

CANCER CELL CULTURE; CANCER RESEARCH; CONCENTRATION RESPONSE; DRUG MECHANISM; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL DIVISION; DRUG RESISTANCE; ESTRAMUSTINE; ESTROGENS; HORMONES; HUMANS; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS; RESEARCH; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0030924253     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970515)31:3<198::AID-PROS9>3.0.CO;2-H     Document Type: Review

References (28)

1. Merchant DJ: Primary culture as an in vitro model. In Coffey DS, Bruchovsky N, Gardner WA Jr, Resnick MI, Karr JP (eds): "Current Concepts and Approaches to the Study of Prostate Cancer." New York: Alan R. Liss, 1987, pp 473-495.
2. van Steenbrugge GJ: Transplantable human prostate cancer (PC-82) in athymic nude mice: A model for the study of androgen-regulated tumor growth. Ph.D. Thesis, Ersamus University, Rotterdam, 1988.
3. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF: Isolation of a human prostatic carcinoma cell line (DU 145). Int J Cancer 21:274-281, 1978.
4. Mickey DD, Stone KR, Wunderli H, Mickey GH, Vollmer RT, Paulson DF: Heterotransplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 37:4049-4058, 1977.
5. Mickey DD, Stone KR, Wunderli H, Mickey GH, Paulson DF: Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice. In Murphy GP (ed): "Models for Prostate Cancer." New York: Alan R. Liss, 1980, pp 67-84.
6. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16-23, 1979.
7. Horoszewicz JS, Leong SS, Chu TM, Friedman M, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: A new model for studies on human prostatic carcinoma. Proc Am Assoc Cancer Res 20:212, 1979.
8. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA: The LNCaP cell line - A new model for studies on human prostatic carcinoma. In Murphy GP (ed): "Models for Prostate Cancer." New York: Alan R. Liss, 1980, pp 115-132.
9. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-1818, 1983.
10. Connolly JM, Rose DP: Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 12:55-63, 1988.
11. Schuurmans ALG, Bolt J, Mulder E: Androgen receptor mediated growth and epidermal growth factor receptor induction in the human prostate carcinoma cell line LNCaP. In: "Abstracts of the 6th Congress of the European Society for Urological Oncology and Endocrinology." 1988, p 27.
12. Schuurmans ALG, Bolt J, Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12:55-63, 1988.
13. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper CG, Jenster G, Trapman J, Brinkman AO, Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to androgens. J Steroid Biochem Mol Biol 41:665-669, 1992.
14. Veldscholte F, Berevoets C, Brinkmann A, Grootegoed J, Mulder E: Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat shock protein interaction, and transcription activation. Biochemistry 31:2293-2399, 1992.
15. van Steenbrugge GJ, Uffelen CJ, Bolt J, Schröder F: The human prostatic cell line LNCaP and its derived sublines: An in vitro model for the study of androgen sensitivity. J Steroid Biochem Mol Biol 40:207-214, 1991.
16. König JJ, Kamst E, Hagemeijer A, Romijn JC, Horoszewicz JS, Schröder FH: Cytogenetic characterization of several androgen-responsive and -unresponsive sublines of the human prostatic carcinoma cell line LNCaP. Urol Res 17:79-86, 1989.
17. Lundin A, Hasenson M, Persson J, Pousette Å: Estimation of biomass in growing cell lines by adenosine triphosphate assay. In DeLuca M, McElroy W (eds): "Bioluminescence and Chemiluminescence, Part B." Academic Press, 1986, pp 27-42.
18. Hasenson M, Hartley-Asp B, Kihlfors C, Lundin A, Gustafsson J-Å, Pousette Å: Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r. Prostate 7:183-194, 1985.
19. Zhao X, van Steenbrugge GJ, Schröder F: Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor. Urol Res 16:1-5, 1988.
20. Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Å, Stege R, von Schoultz B: A comparison of androgen status in patients with prostatic cancer, treated with oral or parenteral estrogens or by orchidectomy. Prostate 14:177-182, 1989.
21. Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Å, von Schoultz B: Single drug parenteral estrogen treatment in prostatic cancer: A study of two maintenance dose regimens. Prostate 14:183-188, 1989.
22. Von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Å, Stege R: Estrogen therapy and liver function - Metabolic effects of oral and parenteral polyestradiol phosphate. Prostate 14:389-392, 1989.
23. Forsgren B, Björk P, Carlström K, Gustafsson J-Å, Pousette Å, Högberg B: Purification and distribution of a major protein in the rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17β. Proc Natl Acad Sci USA 76:3149-3153, 1979.
24. Hasenson M, Lundh B, Hartley-Asp B, Pousette Å: Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r. Urol Res 16:1-5, 1988.
25. 3H-estramustine in two human prostatic carcinoma cell lines, LNCaP and LNCaP-r. Urol Res 17:103-106, 1989.
26. Hasenson M, Lundh B, Stege R, Carlström K, Pousette Å: PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: Relation to hormone sensitivity and to cytological grading. Prostate 14:83-90, 1989.
27. Stege R, Tribukait B, Lundh B, Carlström K, Pousette Å, Hasenson M: Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 148:833-837, 1992.
28. Wu H, Hsieh J, Gleave M, Brown N, Pathak S, Chung L: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 57:406-412, 1994.